Bone mineral density decline following denosumab discontinuation might not be attenuated with previous bisphosphonate therapy

2018 ◽  
Author(s):  
Miha Japelj ◽  
Gaj Vidmar ◽  
Antonela Sabati Rajic ◽  
Marija Pfeifer ◽  
Tomaz Kocjan
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Bisphosphonate Therapy ◽  
Mineral Density

The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women

2012 ◽  
Vol 25 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Kira B. Harris ◽  
Kimberly L. Nealy ◽  
Delilah J. Jackson ◽  
Phillip L. Thornton
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Nuclear Factor Κb ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Cost Of Health Care ◽  
Therapy Studies

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal women worldwide. Treatment of osteoporosis has been ubiquitous throughout the developed world since the mid-1990s, most notably with the introduction of bisphosphonates in 1995. Nonetheless, the incidence of hip fractures increased by 25% between 1990 and 2000, despite advances in osteoporosis therapy. Studies indicate that bone density increases over the first 3 years of bisphosphonate therapy and then plateaus or perhaps even declines, placing these patients at greater risk of fracture. Since hip fractures are associated with increased morbidity, mortality, and increased cost of health care, improvements in treating osteoporosis are critical. Denosumab is a novel monoclonal antibody targeted against the receptor activator of nuclear factor-κB ligand (RANKL) that inhibits osteoclast activity. Initial data suggest that denosumab increases bone mineral density for greater than 3 years. Of greater importance, denosumab has been shown to decrease vertebral fractures by 68%, nonvertebral fractures by 19%, and hip fractures by 42% for at least 36 months. Data also indicate that the safety profile of denosumab is equivalent to other drugs used in osteoporosis management, but potential risks of immunosuppression and cancer have been hypothesized.

Bisphosphonate Therapy for Reduced Bone Mineral Density During Treatment of Acute Lymphoblastic Leukemia in Childhood and Adolescence

2007 ◽  
Vol 29 (9) ◽  
pp. 613-616 ◽  
Author(s):  
Christopher Lethaby ◽  
John Wiernikowski ◽  
Alessandra Sala ◽  
Marissa Naronha ◽  
Colin Webber ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Acute Lymphoblastic Leukemia ◽  
Bone Mineral ◽  
Lymphoblastic Leukemia ◽  
Bisphosphonate Therapy ◽  
Childhood And Adolescence ◽  
Mineral Density

Bone Mineral Density and Bone Turnover Markers Under Bisphosphonate Therapy Used in the First Year After Liver Transplantation

2016 ◽  
Vol 21 ◽  
pp. 241-249 ◽  
Author(s):  
Ewa Nowacka-Cieciura ◽  
Anna Sadowska ◽  
Marek Pacholczyk ◽  
Andrzej Chmura ◽  
Olga Tronina ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Liver Transplantation ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Bisphosphonate Therapy ◽  
First Year ◽  
Mineral Density ◽  
Turnover Markers

scholarly journals Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease

2007 ◽  
Vol 13 (6) ◽  
pp. 683-690 ◽  
Author(s):  
Paul A. Carpenter ◽  
Paul Hoffmeister ◽  
Charles H. Chesnut ◽  
Barry Storer ◽  
Paula M. Charuhas ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Graft Versus Host Disease ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Host Disease ◽  
Graft Versus Host

Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice

2012 ◽  
Vol 24 (4) ◽  
pp. 1483-1489 ◽  
Author(s):  
D. Weycker ◽  
L. Lamerato ◽  
S. Schooley ◽  
D. Macarios ◽  
T. Siu Woodworth ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Clinical Practice ◽  
Bone Mineral ◽  
Bisphosphonate Therapy ◽  
Mineral Density

scholarly journals Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Hidefumi Koiwai ◽  
Mikio Kamimura ◽  
Jun Takahashi ◽  
Yukio Nakamura ◽  
Hiroyuki Kato
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Fragility Fractures ◽  
Spinal Fractures ◽  
Lumbar Bone Mineral Density ◽  
Bone Fragility ◽  
Bisphosphonate Therapy ◽  
Japanese Woman ◽  
Mineral Density ◽  
Multiple Fractures

Abstract Background Osteoporosis is a serious disease that causes bone fragility fractures and increases mortality. Bisphosphonates are the first-line drugs for osteoporosis. However, the gains in bone mineral density by use of bisphosphonates alone are limited. Case presentation We describe the clinical outcome of a Japanese woman with osteoporosis treated with bisphosphonates after multiple spinal fractures. After 3 years of treatment with the bisphosphonate alendronate, her lumbar bone mineral density and bilateral hip bone mineral density markedly increased by 61.9% and 32.5%, respectively. Conclusion We considered that our patient’s multiple fractures had caused a decrease in bone mineral density, which naturally improved with fracture healing to enhance the increase in bone mineral density with bisphosphonate treatment.

scholarly journals Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy

2020 ◽  
Vol 13 ◽  
pp. 117955142097240
Author(s):  
Rebecca Ronsley ◽  
Nazrul Islam ◽  
Mehima Kang ◽  
Helen Nadel ◽  
Christopher Reilly ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Bone Mineral ◽  
Comparative Effectiveness ◽  
Fragility Fractures ◽  
Estimating Equation ◽  
Treated Group ◽  
Bisphosphonate Therapy ◽  
Mineral Density

The objective of this study was to estimate the comparative effectiveness of bisphosphonate therapy on bone mineral density (BMD) in patients with corticosteroid-treated Duchenne muscular dystrophy (DMD). A retrospective, comparative effectiveness study evaluating changes in BMD and fragility fractures in patients with DMD presenting to British Columbia Children’s Hospital from 1989 to 2017 was conducted. Marginal structural generalized estimating equation models weighted by stabilized inverse-probability of treatment weights were used to estimate the comparative effectiveness of therapy on BMD. Of those treated with bisphosphonates (N = 38), 7 (18.4%), 17 (44.7%), and 14 (36.8%) cases were treated with pamidronate, zoledronic acid, or a combination of both, respectively, while 36 cases of DMD were untreated. Mean age of bisphosphonate initiation was 9.2 (SD 2.7) years. Mean fragility fractures declined from 3.5 to 1.0 following bisphosphonate therapy. Compared to the treated group, the untreated group had an additional 0.63-SD decrease (95% confidence interval [CI]: −1.18, −0.08, P = .026) in total BMD and an additional 1.04-SD decrease (95% CI: −1.74, −0.34; P = .004) in the left hip BMD, but the change in lumbar spine BMD (0.15, 95% CI: −0.36, 0.66; P = .57) was not significant. Bisphosphonate therapy may slow the decline in BMD in boys with corticosteroid-treated DMD compared to untreated counterparts. Total number of fragility fractures decreased following bisphosphonate therapy.

The influence of bone mineral density and bisphosphonate therapy on the determinants of oral health and changes on dental panoramic radiographs in postmenopausal women

2016 ◽  
Vol 21 (1) ◽  
pp. 151-157 ◽  
Author(s):  
Olja Grgić ◽  
Branka Kovačev-Zavišić ◽  
Tanja Veljović ◽  
Jovanka Novaković-Paro ◽  
Tatjana Maravić ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Oral Health ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Panoramic Radiographs
Sign in / Sign up

Export Citation Format

Share Document